Search Browse Earnings

IMMUNIC, INC.

Nasdaq:IMUX

Pharmaceutical Preparations·NEW YORK, X1

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

IMMUNIC, INC. — SlamSEC

Revenue

—

Adj. EBITDA

-$97.9M

FY 2025

Net Income

-$100.5M

FY 2025

EPS (Diluted)

-$1.00

FY 2025

Stock Price

$1.25

+12.2%

2026-03-06

52W Range

$0.51 – $1.35

P/E Ratio

-1.2x

Market Cap

$162.4M

Cash

$35.7M

FY 2025

Total Debt

—

Net Cash

$35.7M

Enterprise Value

$126.8M

Debt / EBITDA

0.4x

FY 2025

EV / EBITDA

-1.3x

Employees

66

FY 2025

CEO

Vitt Daniel

CFO

Whaley Glenn